Solid Biosciences
SLDB
75 hedge funds and large institutions have $648M invested in Solid Biosciences in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 21 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 16
1.05% more ownership
Funds ownership: 3.5% → 4.55% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
5% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 21
1% less funds holding
Funds holding: 76 → 75 (-1)
26% less capital invested
Capital invested by funds: $878M → $648M (-$229M)
40% less call options, than puts
Call options by funds: $3.88M | Put options by funds: $6.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$123M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$27.2M |
| 3 |
Jennison Associates
New York
|
+$24.7M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$19.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$40.5M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$18.9M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$13.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.61M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.43M |
SLDB Hedge Fund Activity: Q4 2018 in Review
75 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q4 2018, worth a combined $648M — down 26% from $878M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of SLDB and 20 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 28 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $123M. The largest seller was JP Morgan Chase, cutting an estimated $40.5M.
- 75 institutional investors held Solid Biosciences (SLDB) as of Q4 2018, down from 76 in Q3 2018.
- Funds reported $648M of Solid Biosciences stock for Q4 2018, down 26% quarter-over-quarter.
- 20 funds opened new Solid Biosciences positions in Q4 2018 and 21 closed out, a net change of -1 holder.
- The largest Solid Biosciences buyer in Q4 2018 was Perceptive Advisors, an estimated $123M added.
- The largest Solid Biosciences seller in Q4 2018 was JP Morgan Chase, an estimated $40.5M sold.
Based on aggregated 13F filings for Q4 2018.